Themis Medicare Ltd
Themis Medicare Ltd Q4 FY26 Results & Presentation Highlights: Revenue ₹76.53 Cr, PAT ₹8.89 Cr
Q4 FY26 investor presentation: what the company reported on revenue, margins and projects.
Based on Themis Medicare Ltd's Q4 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.
The short version
Q4 FY26 Net Revenue: ₹76.53 crore, up 6.7% YoY from ₹71.70 crore in Q4 FY25 (Page 8). Q4 FY26 EBITDA: ₹3.76 crore (up from a loss of ₹5.78 crore in Q4 FY25), margin 4.92% (vs.
From Themis Medicare Ltd's Q4 FY26 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Q4 FY26 Net Revenue: ₹76.53 crore, up 6.7% YoY from ₹71.70 crore in Q4 FY25 (Page 8).
- FY26 Net Revenue: ₹342.24 crore, down 15.6% YoY from ₹405.51 crore in FY25 (Page 9).
- Quarterly Revenue trend: Q1 FY26 ₹97.6 crore, Q2 FY26 ₹78.0 crore, Q3 FY26 ₹90.1 crore, Q4 FY26 ₹76.5 crore (Page 7).
- Sales mix shifting toward a higher share of API revenue; API business showed continued growth, partially offset by softness in formulations (Page 8).
- No explicit volume figures stated.
2 more points management made on revenue & sales performance
Profitability & Margins
See what Themis Medicare Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- The presentation mentions vertically integrated manufacturing facilities at Haridwar, Hyderabad, and Vapi with state-of-art capabilities for formulations and synthetic APIs but does not specify new plant projects or expansions explicitly.
- Capacity details:
- Formulations (Haridwar): Tablets (520 mn), Ointments (9 mn tubes), Ampoules (36 mn), Vials (12 mn), Pre-filled syringes (6 mn) per annum.
- Synthetic APIs: Hyderabad (120 MT), Vapi (191 MT) per annum.
- No explicit mention of new capex amounts or ongoing capacity expansions in the document.
2 more points management made on capital expenditure plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Themis Medicare Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points management made on order book & pipeline
Themis Medicare Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹77 Cr, net profit ₹9 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Themis Medicare Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Anuh Pharma Ltd (Q4 FY26)
202.12 Cr., a 2.50% increase quarter-on-quarter (Page 14) . Key investor presentation takeaways from Anuh Pharma Ltd's Q4 FY26 investor presentation — and how i
- Remus Pharmaceuticals Ltd (Q4 FY26)
Quarterly Revenue (H2-FY26):** INR 4,534 Mn, up 30.4% YoY from INR 3,478 Mn in H2-FY25 . Key investor presentation takeaways from Remus Pharmaceuticals Ltd's Q4
- Lincoln Pharmaceuticals Ltd (Q4 FY26)
EBITDA: ₹26 crore, a 3% year-on-year increase . Key investor presentation takeaways from Lincoln Pharmaceuticals Ltd's Q4 FY26 investor presentation — and how i
- Kopran Ltd (Q4 FY26)
6,166 Lakhs increase (~35.8% growth) . Key investor presentation takeaways from Kopran Ltd's Q4 FY26 investor presentation — and how it ranks against sector pee
Frequently Asked Questions
What were Themis Medicare Ltd Q4 FY26 results?
Q4 FY26 Net Revenue: ₹76.53 crore, up 6.7% YoY from ₹71.70 crore in Q4 FY25 (Page 8). Q4 FY26 EBITDA: ₹3.76 crore (up from a loss of ₹5.78 crore in Q4 FY25), margin 4.92% (vs.
What is Themis Medicare Ltd share price analysis?
Themis Medicare Ltd currently shows a neutral. The stock trades at a P/E of N/A with a market cap of ₹1,142 Cr. Investors should review the full earnings analysis for detailed insights.
Is Themis Medicare Ltd planning capital expenditure?
The presentation mentions vertically integrated manufacturing facilities at Haridwar, Hyderabad, and Vapi with state-of-art capabilities for formulations and synthetic APIs but does not specify new plant projects or expansions explicitly.
Keep Themis Medicare Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.